Form 4: Tandem Diabetes Care EVP Elizabeth Gasser Reports Stock Transactions

Elizabeth Gasser, EVP and Chief Strategy Officer at Tandem Diabetes Care, reports acquisition and disposal of common stock and derivative securities, including restricted stock units and performance stock units.

Summary

• Elizabeth Gasser, EVP and Chief Strategy Officer of Tandem Diabetes Care, filed a Form 4 detailing changes in beneficial ownership.
• On May 28, 2024, 373 shares of common stock were acquired through the vesting of restricted stock units.
• Also on May 28, 2024, 134 shares were disposed of to satisfy tax withholding requirements at a price of $51.73 per share.
• As of May 28, 2024, Gasser directly owns 11,749 shares of Tandem Diabetes Care common stock.
• On May 23, 2024, Gasser was awarded 13,161 restricted stock units (RSUs) and 13,160 performance stock units (PSUs).
• The RSUs awarded on May 23, 2024, vest over time, starting with 33% on 5/15/2025, and the remaining shares vesting in eight equal quarterly installments thereafter.
• The PSUs awarded on May 23, 2024, vest based on the achievement of pre-defined performance metrics as of December 31, 2026, and the number of shares issued may range from 0% to 200% of the amount specified above.
• The RSUs awarded on May 27, 2020, vest as to 25% of the total number of shares subject to the RSU on the one year anniversary of the grant date, and the remaining shares shall vest in twelve equal quarterly installments thereafter.

Sentiment

Score: 6

Explanation: The sentiment is neutral as the filing primarily reflects routine stock transactions related to executive compensation. The granting of RSUs and PSUs is generally positive, but the disposal of shares for tax obligations is a standard procedure.

Positives

• The granting of RSUs and PSUs to the EVP suggests continued alignment of executive compensation with company performance and shareholder value.

Negatives

• The disposal of shares to cover tax obligations, while standard, slightly reduces the executive's direct holdings.

Risks

• The vesting of PSUs is contingent on achieving pre-defined performance metrics, which introduces uncertainty regarding the actual number of shares that will be issued.
• The value of the stock could fluctuate, impacting the overall value of the holdings.

Future Outlook

The vesting of RSUs and PSUs is subject to continued service and, in the case of PSUs, the achievement of performance metrics.

Industry Context

Form 4 filings are a routine part of executive compensation and provide transparency into insider transactions, which are closely monitored by investors.

Comparison to Industry Standards

• Executive compensation packages including RSUs and PSUs are common in the medical device industry to incentivize performance and align executive interests with shareholder value.
• Companies like Insulet and Dexcom also utilize similar equity-based compensation plans for their executives.

Stakeholder Impact

• Shareholders can monitor insider transactions to gain insights into management's perspective on the company's value.
• Employees may be impacted by the company's performance, which affects the vesting of PSUs.

Next Steps

• Continued monitoring of insider transactions and company performance to assess the value of equity-based compensation.

Key Dates